Packer, Milton

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 264

Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity

Packer, M. (2018) · Circulation

Heart Failure Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 263

SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action

Packer, M. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 247

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Butler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., et al. (2022) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 206

Cardiovascular Drug Development

Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology

Pharmaceutical Economics and PolicyPharmaceutical industry and healthcare

Cited by 202

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology

Cardiovascular Disease and AdiposityHeart Failure Treatment and Management

Cited by 200

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 186

Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease

Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 185

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Obesity-Related Heart Failure With a Preserved Ejection Fraction

Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 172

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 166

Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes

Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 131

Empagliflozin and major renal outcomes in heart failure

Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 112

Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors

Packer, M. (2020) · Journal of Cardiac Failure

Gout, Hyperuricemia, Uric AcidHeart Failure Treatment and Management

Cited by 95

Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress

Packer, M. (2021) · Cardiovascular Research

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 86

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

Packer, M., Butler, J., Zeller, C., Pocock, S. J., Brueckmann, M., Ferreira, J. P., Filippatos, G., Usman, M. S., Zannad, F., & Anker, S. D. (2023) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 86

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 74

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

Kotecha, D., Gill, S. K., Flather, M. D., Holmes, J., Packer, M., Rosano, G., Böhm, M., McMurray, J. J. V., Wikstrand, J., Anker, S. D., et al. (2019) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 71

Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials

Ferreira, J. P., Saraiva, F., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D., Packer, M., Zannad, F., et al. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 65

Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction

Malik, A., Masson, R., Singh, S., Wu, W.-C., Packer, M., Pitt, B., Waagstein, F., Morgan, C. J., Allman, R. M., Fonarow, G. C., et al. (2019) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 55

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 49

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 42

Health‐related quality of life outcomes in PARAGON‐HF

Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 33

Data sharing in medical research

Packer, M. (2018) · BMJ

Research Data Management PracticesAcademic Publishing and Open Access

Cited by 27